UCH‐L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease
暂无分享,去创建一个
G. Scott | P. Robinson | H. Ardley | S. A. Rose | N. Tan | Helen C. Ardley
[1] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[2] Takeshi Iwatsubo,et al. Aggresomes Formed by α-Synuclein and Synphilin-1 Are Cytoprotective* , 2004, Journal of Biological Chemistry.
[3] K. Baek,et al. DUB-1A, a Novel Deubiquitinating Enzyme Subfamily Member, Is Polyubiquitinated and Cytokine-inducible in B-lymphocytes* , 2004, Journal of Biological Chemistry.
[4] Barrington G. Burnett,et al. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. , 2003, Human molecular genetics.
[5] P. Lockhart,et al. RING finger 1 mutations in Parkin produce altered localization of the protein. , 2003, Human molecular genetics.
[6] B. Ghetti,et al. Ubiquitination of α-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function* , 2003, Journal of Biological Chemistry.
[7] S. Endo,et al. A novel ubiquitin‐specific protease, synUSP, is localized at the post‐synaptic density and post‐synaptic lipid raft , 2003, Journal of neurochemistry.
[8] G. Scott,et al. Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. , 2003, Molecular biology of the cell.
[9] N. Wood,et al. Parkin is recruited into aggresomes in a stress-specific manner: over-expression of parkin reduces aggresome formation but can be dissociated from parkin's effect on neuronal survival. , 2003, Human molecular genetics.
[10] David W. Miller,et al. L166P Mutant DJ-1, Causative for Recessive Parkinson's Disease, Is Degraded through the Ubiquitin-Proteasome System* , 2003, Journal of Biological Chemistry.
[11] Hiroshi Nakayama,et al. PGP9.5 overexpression in esophageal squamous cell carcinoma. , 2003, Hepato-gastroenterology.
[12] Kaori Nishikawa,et al. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. , 2003, Human molecular genetics.
[13] C. V. van Duijn,et al. Parkinson's disease: piecing together a genetic jigsaw. , 2003, Brain : a journal of neurology.
[14] James E Bear,et al. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[15] T. Hirokawa,et al. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. , 2003, Biochemical and biophysical research communications.
[16] P. Amouyel,et al. S18Y polymorphism in the UCH‐L1 gene and Parkinson's disease: Evidence for an age‐dependent relationship , 2003, Movement disorders : official journal of the Movement Disorder Society.
[17] C. Warren Olanow,et al. Altered Proteasomal Function in Sporadic Parkinson's Disease , 2003, Experimental Neurology.
[18] M. Mouradian,et al. Parkin Accumulation in Aggresomes Due to Proteasome Impairment* , 2002, The Journal of Biological Chemistry.
[19] D. Perl,et al. Aggresome‐related biogenesis of Lewy bodies , 2002, The European journal of neuroscience.
[20] P. Lansbury,et al. The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.
[21] N. Shastri,et al. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum , 2002, Nature.
[22] R. Mayer,et al. The ubiquitin-proteasome pathway of intracellular proteolysis. , 2002, Essays in biochemistry.
[23] A. Destée,et al. Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease , 2002, Neuroscience Letters.
[24] E. Sztul,et al. Hassles with Taking Out the Garbage: Aggravating Aggresomes , 2002, Traffic.
[25] B. Hyman,et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. , 2002, The American journal of pathology.
[26] S. Shin,et al. Formation and Removal of α-Synuclein Aggregates in Cells Exposed to Mitochondrial Inhibitors* , 2002, The Journal of Biological Chemistry.
[27] C. Woods,et al. Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36 , 2001, Journal of medical genetics.
[28] L. Petrucelli,et al. Co-association of parkin and α-synuclein , 2001 .
[29] D. Sulzer,et al. Proteasomal inhibition leads to formation of ubiquitin/α‐synuclein‐immunoreactive inclusions in PC12 cells , 2001, Journal of neurochemistry.
[30] Barry Halliwell,et al. Failure of the ubiquitin–proteasome system in Parkinson's disease , 2001, Nature Reviews Neuroscience.
[31] Nobutaka Hattori,et al. Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.
[32] A. Markham,et al. Features of the Parkin/Ariadne-like Ubiquitin Ligase, HHARI, That Regulate Its Interaction with the Ubiquitin-conjugating Enzyme, UbcH7* , 2001, The Journal of Biological Chemistry.
[33] M. Sherman,et al. Intracellular Aggregation of Polypeptides with Expanded Polyglutamine Domain Is Stimulated by Stress-Activated Kinase Mekk1 , 2001, The Journal of cell biology.
[34] H. Lehrach,et al. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. , 2001, Molecular biology of the cell.
[35] R. Takahashi,et al. Implications of Protein Degradation in Aging , 2001, Annals of the New York Academy of Sciences.
[36] A. Bentivoglio,et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. , 2001, American journal of human genetics.
[37] A. Weissman. Ubiquitin and proteasomes: Themes and variations on ubiquitylation , 2001, Nature Reviews Molecular Cell Biology.
[38] A. Goldberg,et al. Cellular Defenses against Unfolded Proteins A Cell Biologist Thinks about Neurodegenerative Diseases , 2001, Neuron.
[39] K. McNaught,et al. Proteasomal function is impaired in substantia nigra in Parkinson's disease , 2001, Neuroscience Letters.
[40] Giladi,et al. Failure to find mutations in ubiquitin carboxy-terminal hydrolase L1 gene in familial Parkinson's disease. , 2000, Parkinsonism & related disorders.
[41] S. Kubo,et al. Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. , 2000, Parkinsonism & related disorders.
[42] Shinsei Minoshima,et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.
[43] A. Markham,et al. Regulation and function of the interaction between the APC tumour suppressor protein and EB1 , 2000, Oncogene.
[44] S. Warren,et al. Aberrant Protein Deposition and Neurological Disease* , 1999, The Journal of Biological Chemistry.
[45] S. H. Baek,et al. Deubiquitinating enzymes: their diversity and emerging roles. , 1999, Biochemical and biophysical research communications.
[46] Harry T Orr,et al. Mutation of the E6-AP Ubiquitin Ligase Reduces Nuclear Inclusion Frequency While Accelerating Polyglutamine-Induced Pathology in SCA1 Mice , 1999, Neuron.
[47] M. Farrer,et al. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson’s disease , 1999, Neurology.
[48] E. Sztul,et al. Characterization and Dynamics of Aggresome Formation by a Cytosolic Gfp-Chimera✪ , 1999, The Journal of cell biology.
[49] S. Goodman,et al. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. , 1999, The American journal of pathology.
[50] S. Minoshima,et al. Immunohistochemical and subcellular localization of parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients , 1999, Annals of neurology.
[51] R. Kopito,et al. Aggresomes: A Cellular Response to Misfolded Proteins , 1998, The Journal of cell biology.
[52] A. Lang,et al. Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.
[53] Steven Finkbeiner,et al. Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.
[54] Georg Auburger,et al. The ubiquitin pathway in Parkinson's disease , 1998, Nature.
[55] A. Goldberg,et al. Proteasome inhibitors: valuable new tools for cell biologists. , 1998, Trends in cell biology.
[56] S. W. Davies,et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.
[57] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[58] Mark Turmaine,et al. Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.
[59] A. Goldberg,et al. Proteasome Inhibition Leads to a Heat-shock Response, Induction of Endoplasmic Reticulum Chaperones, and Thermotolerance* , 1997, The Journal of Biological Chemistry.
[60] Hidefumi Ito,et al. Immunocytochemical Co‐localization of the Proteasome in Ubiquitinated Structures in Neurodegenerative Diseases and the Elderly , 1997, Journal of neuropathology and experimental neurology.
[61] S. Nigam,et al. Perturbations in maturation of secretory proteins and their association with endoplasmic reticulum chaperones in a cell culture model for epithelial ischemia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[62] Hisashi Ito,et al. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. , 1996, Journal of biochemistry.
[63] R. Baker,et al. Control of Cell Fate by a Deubiquitinating Enzyme Encoded by the fat facets Gene , 1995, Science.
[64] M. Fujimuro,et al. Production and characterization of monoclonal antibodies specific to multi‐ubiquitin chains of polyubiquitinated proteins , 1994, FEBS letters.
[65] D. Dickson,et al. Pathology and Biology of the Lewy Body , 1993, Journal of neuropathology and experimental neurology.
[66] J. Lowe,et al. Ubiquitin carboxyl‐terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases , 1990, The Journal of pathology.
[67] K D Wilkinson,et al. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. , 1989, Science.
[68] C. Olanow,et al. Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson's disease , 2003, Annals of neurology.
[69] C. Olanow,et al. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. , 2002, Neuroscience letters.
[70] A. Nakao,et al. PGP9.5 as a marker for invasive colorectal cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[71] A. Goldberg,et al. Proteasome inhibitors: from research tools to drug candidates. , 2001, Chemistry & biology.
[72] C. Pickart,et al. Mechanisms underlying ubiquitination. , 2001, Annual review of biochemistry.
[73] L. Petrucelli,et al. Co-association of parkin and alpha-synuclein. , 2001, Neuroreport.
[74] M G Spillantini,et al. Alpha-synuclein in Lewy bodies. , 1997, Nature.